GlaxoSmithKline PLC
LSE:GSK

Watchlist Manager
GlaxoSmithKline PLC Logo
GlaxoSmithKline PLC
LSE:GSK
Watchlist
Price: 1 783 GBX -2.06% Market Closed
Market Cap: 72.4B GBX

Relative Value

The Relative Value of one GSK stock under the Base Case scenario is 2 615.97 GBX. Compared to the current market price of 1 783 GBX, GlaxoSmithKline PLC is Undervalued by 32%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GSK Relative Value
Base Case
2 615.97 GBX
Undervaluation 32%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
20
vs Industry
52
Median 3Y
2
Median 5Y
2
Industry
2.6
Forward
2.1
vs History
42
vs Industry
20
Median 3Y
13.4
Median 5Y
12.6
Industry
21.7
Forward
20.8
vs History
25
vs Industry
40
Median 3Y
9
Median 5Y
8.3
Industry
16.6
vs History
61
vs Industry
14
Median 3Y
14.5
Median 5Y
23.3
Industry
22.5
vs History
33
vs Industry
16
Median 3Y
4.5
Median 5Y
4.3
Industry
2.3
vs History
23
vs Industry
45
Median 3Y
2.3
Median 5Y
2.3
Industry
2.9
Forward
2.5
vs History
28
vs Industry
58
Median 3Y
3.2
Median 5Y
3.3
Industry
5.5
vs History
34
vs Industry
41
Median 3Y
6.7
Median 5Y
6.8
Industry
13.1
Forward
7.5
vs History
30
vs Industry
39
Median 3Y
8.9
Median 5Y
9.3
Industry
16.6
Forward
9.1
vs History
31
vs Industry
36
Median 3Y
10.7
Median 5Y
9.8
Industry
15.8
vs History
28
vs Industry
22
Median 3Y
16.8
Median 5Y
15.2
Industry
19.1
vs History
7
vs Industry
37
Median 3Y
1.8
Median 5Y
1.7
Industry
1.9

Multiples Across Competitors

GSK Competitors Multiples
GlaxoSmithKline PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
GlaxoSmithKline PLC
LSE:GSK
71.8B GBP 2.2 13.1 7 9.9
US
Eli Lilly and Co
NYSE:LLY
929B USD 15.6 50.5 33.9 36.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
481.1B USD 5.2 19.2 15.7 20.4
CH
Roche Holding AG
SIX:ROG
251.1B CHF 4.1 26.6 11.4 13.3
UK
AstraZeneca PLC
LSE:AZN
210.8B GBP 4.8 29.8 108.1 158.2
CH
Novartis AG
SIX:NOVN
205B CHF 4.5 17.7 11.2 14.5
US
Merck & Co Inc
NYSE:MRK
241B USD 3.8 12.7 9.1 10.7
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK 4.2 12.8 9 10.4
IE
Endo International PLC
LSE:0Y5F
202.5B USD 87.3 -69.3 321.2 805.4
US
Pfizer Inc
NYSE:PFE
144B USD 2.3 14.7 7.5 10.2
P/E Multiple
Earnings Growth PEG
UK
GlaxoSmithKline PLC
LSE:GSK
Average P/E: 21.9
13.1
17%
0.8
US
Eli Lilly and Co
NYSE:LLY
50.5
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.2
29%
0.7
CH
Roche Holding AG
SIX:ROG
26.6
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.8
38%
0.8
CH
Novartis AG
SIX:NOVN
17.7
17%
1
US
Merck & Co Inc
NYSE:MRK
12.7
15%
0.8
DK
Novo Nordisk A/S
CSE:NOVO B
12.8
4%
3.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -69.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.7
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
UK
GlaxoSmithKline PLC
LSE:GSK
Average EV/EBITDA: 398.2
7
5%
1.4
US
Eli Lilly and Co
NYSE:LLY
33.9
33%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
15.7
9%
1.7
CH
Roche Holding AG
SIX:ROG
11.4
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.1
10%
10.8
CH
Novartis AG
SIX:NOVN
11.2
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.1
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9
2%
4.5
IE
E
Endo International PLC
LSE:0Y5F
321.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
1%
7.5
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
UK
GlaxoSmithKline PLC
LSE:GSK
Average EV/EBIT: 1 708.3
9.9
10%
1
US
Eli Lilly and Co
NYSE:LLY
36.4
36%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.4
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.3
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.2
23%
6.9
CH
Novartis AG
SIX:NOVN
14.5
12%
1.2
US
Merck & Co Inc
NYSE:MRK
10.7
8%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
10.4
1%
10.4
IE
E
Endo International PLC
LSE:0Y5F
805.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
8%
1.3